CD274 and melanoma: In general, radiomic/TA can provide novel imaging-based biomarkers to be correlated with a panel of diagnostic, prognostic, and predictive biomarkers, either serological (i.e., LDH), molecular (i.e., TMB), and immunohistochemical (i.e., PD-L1), to support the management of advanced melanoma patients [49,86].